Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Lymphoma, Hodgkin lymphoma, adult
Stage/Subtype:  stage I adult Hodgkin lymphoma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 54 for your search:
Start Over
Stem Cell Transplant for Hematological Malignancy
Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, P30CA015704, NCT01231412
Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 116428, 2012-003438-18, NCT01767467
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Phase: Phase III
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: CB-AB006, 2012-0166, NCT01854567
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 95-024, P30CA008748, MSKCC-95024, NCI-V95-0685, NCT00002663
Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: J0703, NA00005743, NCT00484874
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 montha to 70
Sponsor: Other
Protocol IDs: J1055, NA_00039823, NCT01203722
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2011-001, NCT01416428
Maintenance Lenalidomide in Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 11411, NCT01575860
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2011-203, NCT01609816
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2011-204, NCT01643603
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: BP-HM-001, NCT01744223
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 201303012, NCT01747499
Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-170, NCT01755975
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NU 12H09, NCI-2012-03090, STU00072695, NCT01805037
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 22
Sponsor: Other
Protocol IDs: AAAK8060, NCT02061800
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 13-1406, NCI-2014-01581, IRB13-1406, P30CA014599, NCT02213913
ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ACE-LY-001, NCT02328014
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-179, NCT02341014
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI
Protocol IDs: 150067, 15-C-0067, NCT02356159
ACP-196 in Combination With Pembrolizumab, for Treatment of B-Cell Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ACE-LY-005, NCT02362035
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 2005LS048, UMN-0508M72589, UMN-MT2004-24, UMN-2005LS048, NCT00345865
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 65
Sponsor: Other
Protocol IDs: 2009-0266, NCI-2011-03144, NCT01010217
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 26
Sponsor: Other
Protocol IDs: L 10,321, NYMC 525, NCT01049854
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 18 to 60
Sponsor: NCI, Other
Protocol IDs: CALGB-50801, CDR0000669076, NCI-2011-02034, NCT01118026
Start Over